Display Settings:

Format

Send to:

Choose Destination

    Br J Ophthalmol. 2004 Jan;88(1):17-8.

    Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia.

    Chen C, Louis D, Dodd T, Muecke J.

    Ophthalmic Oncology Unit, Department of Ophthalmology, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia.

    AIM: To report the outcome of topical mitomycin C (MMC) used as adjunctive treatment following primary excision of ocular surface squamous neoplasia (OSSN). METHOD: Prospective, non-comparative interventional case series of 27 primary OSSN lesions from 26 patients treated in a single ocular oncology centre over a 4 year period. RESULT: 27 cases of OSSN received a treatment regimen of surgical excision, followed by topical MMC. Mean follow up of 27 (SD 12) months (range 12-50, median 25 months) revealed zero recurrences. CONCLUSION: MMC treatment following surgical excision decreases the recurrence rate of primary ocular surface neoplasia and should be considered as adjunctive therapy in primary treatment.

    PMID: 14693762 [PubMed - indexed for MEDLINE]

    PMCID: 1771954

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Mitomycin (Mutamycin®)

      Your doctor has ordered the drug mitomycin to help treat your illness. The drug is given by injection into a vein.